文献速递免疫规划慢病防控与筛查

在老年人中间隔2、6或12个月接种2剂佐剂带状疱疹亚单位疫苗的免疫原性、反应原性和安全性:一项III期、随机、开放标签、多中心研究结果

Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
PubMed 文献 · Vaccine · 2017-11-22

这项在美国和爱沙尼亚开展的III期开放标签试验将354名≥50岁成人按1:1:1随机分配,间隔2、6或12个月接种2剂带状疱疹亚单位疫苗(HZ/su)。第2剂后1个月,0、6月程序疫苗应答率为96.5%(97.5%CI:90.4;99.2),0、12月程序为94.5%(97.5%CI:87.6;98.3),均达到预设标准;0、6月程序抗gE几何平均浓度非劣效于0、2月程序,而0、12月程序未达到非劣效标准。所有给药间隔的安全性均可临床接受。

要点

  • 0、6月程序第2剂后1个月疫苗应答率96.5%(97.5%CI:90.4;99.2),达到预设标准。
  • 0、12月程序疫苗应答率94.5%(97.5%CI:87.6;98.3),达到预设标准。
  • 0、6月程序抗gE几何平均浓度非劣效于0、2月程序,0、12月程序未达非劣效标准。

核心结论

  • 0、6月程序接种HZ/su的免疫应答非劣效于0、2月程序。
  • HZ/su在所有给药间隔均表现出可临床接受的安全性特征。

研究设计与样本

  • III期、开放标签、多中心、随机试验,在美国和爱沙尼亚开展。
  • 354名≥50岁成人按1:1:1随机分配,间隔2、6或12个月接种2剂HZ/su(50 µg水痘-带状疱疹病毒糖蛋白E和AS01B佐剂系统)。
  • 346名参与者完成研究,343名纳入符合方案免疫原性队列。

主要发现

  • 第2剂后1个月,0、6月程序疫苗应答率为96.5%(97.5%CI:90.4;99.2),0、12月程序为94.5%(97.5%CI:87.6;98.3),均达到预设标准。
  • 0、6月程序抗gE几何平均浓度非劣效于0、2月程序;0、12月程序未达到非劣效标准。
  • 注射部位疼痛是最常报告的征集性不良事件。
  • 26名参与者各报告至少1起严重不良事件,均未被评估为与接种相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In phase III trials, 2 doses of a herpes zoster (HZ) subunit vaccine (HZ/su; 50 µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) administered 2-months apart in older adults (≥50 and ≥70 years) demonstrated >90% efficacy in preventing HZ and had a clinically acceptable safety profile. Here we report immunogenicity, reactogenicity and safety following administration of 2 HZ/su doses at intervals longer than 2 months. METHODS: In this Phase III, open-label trial conducted in the US and Estonia, 354 adults ≥50 years were randomized 1:1:1 to receive 2 HZ/su doses 2, 6, or 12 months apart. gE-specific humoral immune responses were evaluated at pre-vaccination, 1 and 12 months post-dose 2. Co-primary objectives were to compare immune responses to HZ/su 1 month post-dose 2 when given 6-months or 12-months apart to those administered 2-months apart. For each participant, safety information was collected from dose 1 to 12 months post-dose 2. RESULTS: 346 participants completed the study and 343 were included in the according-to-protocol cohort for immunogenicity. One month post-dose 2, vaccine response rates were 96.5% (97.5% confidence interval [CI]: 90.4; 99.2) and 94.5% (97.5% CI: 87.6; 98.3) for the 0, 6- and 0, 12-month schedules, respectively, both schedules meeting the pre-defined criterion. Non-inferiority of anti-gE geometric mean concentrations was demonstrated for HZ/su administered on 0, 6-month compared to a 0, 2-month schedule; however, HZ/su administered on a 0, 12-month schedule did not meet the non-inferiority criterion. Injection site pain was the most commonly reported solicited adverse event (AE). 26 participants each reported at least 1 serious AE; none were assessed as related to vaccination. CONCLUSIONS: Immune responses to HZ/su administered at 0, 6-month were non-inferior to those elicited by a 0, 2-month schedule. HZ/su exhibited a clinically acceptable safety profile for all dosing intervals. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov (NCT01751165).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Vaccine. 2017. PMID: 29174683. doi:10.1016/j.vaccine.2017.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。